The overall aim of the proposed research is to optimise and apply the range of assays we have developed to assess the genotoxic impact of some key anti-cancer (Gemcitabine) and anti-viral (Remdesivir and Molnupiravir) nucleoside analogues and publish this analysis as proof of principle and advertise the knowledge and expertise we have developed here in Wales. The proposed research involves a new collaboration between Bangor applicants and the recently established company Broken String Biosciences Ltd., which offers assays that are complementary to the assays we have been developing. In the long term, we believe there is significant potential for impact and commercial exploitation of our assays, e.g. by influencing requirements for genotoxic assessment of nucleoside analogue drugs and offering our expertise and novel assays as a commercial service for pharmaceutical companies to assess the on- and off-target effects of candidate nucleoside analogue drugs.

Funding awarded through the Bangor University Innovation and Impact Award (Research Wales Innovation Funding). Value = £45,942